HONG KONG, Mar 31, 2025 - (ACN Newswire via SeaPRwire.com) - Yunkang Group Limited ("Yunkang" or the "Group"; Stock Code: 2325), a leading medical operation services provider in China, has announced its annual results for the year ended December 31, 2024 (the "Reporting Period"). During the year, the Group adhered to its overall business philosophy of “in-depth services and lean operations”, promoted development with innovation, deepened integrated collaboration among “government, industry, academy, research, medicine, application”, accelerated digital application of “AI + medical care”, continuously strengthened refined management, and reduced cost and improved efficiency, demonstrating strong operational resilience.In 2024, due to changes in the macro-environment, intensified competition in the industry as well as its strategic decision to optimize customer structure and product mix, the Group’s performance was temporarily affected. However, relying on its customer-oriented, innovative and coordinated development system, the Group achieved many breakthroughs in product innovation, model innovation, AI + medical digital intelligence and other aspects. The joint construction business with medical institution alliances remained its largest business segment, which accounted for 53.0% of the total revenue, representing an increase of 4.7 percentage points as compared to the same period of the previous year. In addition, featured products in the infection segment achieved rapid growth, laying a solid foundation for the segment’s long-term development. During the Reporting Period, the Group’s total revenue reached RMB711.9 million.Diagnostic testing for medical institution alliances was developing healthily In-depth service empowers customersYunkang is committed to developing an innovative service mode for joint construction of medical institution alliances with “professionalism as the foundation, standardization as the core, digital intelligence as the means, synergization as the goal”. At present, the Group is providing medical technical service solutions to over 1,500 medical institutions in collaboration with medical institution alliances at over 430 on-site diagnostic centers of the alliances to meet their core demands. Through close collaboration – mutual recognition of testing results – with leading regional medical institutions, the Group has helped improve overall regional medical and treatment levels, helping hospitals build specialty departments, improving the efficiency of hierarchical diagnosis and treatment, promoting scientific research and cooperation, etc., thereby providing the public with higher-quality and more efficient diagnosis and treatment services. Dedicated to vigorously driving medical reform in China, during the Reporting Period, Yunkang teamed up with leading provincial-level hospitals, and regional county-level general hospitals to jointly build medical institution alliances to actively promote the construction of medical institution alliances as the bridge that connects the regional testing centers and partner hospitals. Customers are provided with “3+N” tumor, infection, reproductive genetics and +N technical system support, and also support from the in-depth service system, including the operation of diagnostic centers under regional medical institution alliances, access to new technologies or new products, construction services for digital specialty departments, medical cold chain logistics services, quality control services and supply chain services, all in-depth services for empowering demand and the long-term development of hospitals.Focus on “clinical demands” Joint innovation for diagnostic testing achieved remarkable resultsAdhering to the “clinical demands”-oriented service concept, the Group has built a series of high-tech platforms, including high-throughput sequencing, gene chip, high-sensitivity PCR, protein spectrometry, cytogenetics, digital remote pathology, and ultra-micro pathology. During the Reporting Period, the Group introduced nearly 800 new testing items and provided about 3,800 clinical testing items, and more than 10 million specimens were tested for the year. In terms of precision diagnosis and treatment, the Group carried out more than 500 precision diagnosis services using cutting-edge technologies such as high-throughput sequencing, and protein spectrometry, covering five medical fields including infectious diseases, reproductive genetics, solid tumors, blood diseases, and personalized medicine. During the Reporting Period, the Group focused on the construction and development of 58 new items in such fields including infection, tumor, rare genetic diseases and personalized medicine, providing medical institutions nationwide with a more comprehensive range of precision diagnosis solutions to drive the embrace and development of precision medicine. During the Reporting Period, revenue from special testing items increased significantly year-on-year, accounting for a larger percentage of the Group’s overall revenue.The Group has a first-of-its-kind “joint innovation platform for diagnostic testing”, which has played a vital role in expanding its business and boosting competitiveness of its products. Constantly exploring and putting ideas into practice, the Group and dozens of top medical institutions across the country have pursued joint innovation for diagnostic testing and successfully developed more than 10 testing products for different infection syndromes in various fields such as respiratory tract infections and central nervous system infections.Digital application of “AI + medical care” leads the industryThe Group has launched and continuously upgraded its top 10 digital “cloud” systems, covering core areas such as laboratory operations, sales management, human resources, staff training, and customer services. At the same time, it has integrated AI technology into its “cloud” systems to create a one-stop intelligent medical diagnostic solution covering from “sample collection” to “report delivery”, which was comprehensively applied across its multi-technology platforms in medical laboratories, with the core concepts of “Internet+” and “precision diagnosis” to create a series of intelligent diagnostic platforms. In the Reporting Period, the Group’s self-developed digital IT platform with full intellectual property rights – the remote pathology consultation platform – covered over 800 medical testing items, assisting nearly 300 medical institutions nationwide in enhancing their pathology diagnostic capabilities and benefiting more than 200 million patients in rural areas.Regarding the application of AI-assisted diagnosis, the Group adheres to the strategy of “introducing one item once it is mature” and closely follows industry development trends. It has introduced items such as pathological DNA polyploid AI-assisted diagnosis, cervical liquid-based cell AI-assisted diagnosis, and chromosome AI analysis, all proven effective and have greatly enhanced diagnostic efficiency. During the Reporting Period, the Group focused on the field of infectious diseases and developed its first infectious disease data product, the “Yunkang Respiratory Pathogen Detection Positivity Rate Analysis Report”. The product officially obtained data product certification and was listed on the Guangzhou Data Exchange in January 2025, marking a milestone step for the Group in the field of compliant data transactions, effectively unlocking data value. Currently, having access to the DeepSeek large model, the Group aims to achieve comprehensive innovation in medical testing and diagnostics through inclusive technology, precision service and intelligent management.Collaborative and integrated development of “government, industry, academy, research, medicine, application” to facilitate industrial upgradeDuring the Year, the Group collaborated with various institutions to facilitate industrial upgrade based on a unique innovative industrial model, including:- Collaboration with The People’s Government of Ouhai, Wenzhou City and Wenzhou Medical University’s core areas in biomedical industry to promote construction of a number of key projects including a joint innovation and transformation platform, a public service platform, a medical big data research platform, a regional diagnostic sharing center and a training base for innovative talent, to the end of facilitating quick transformation of scientific research results for industrial applications;- Collaboration with The Zhangjiang Research Institute of Fudan University to jointly establish a “Collaborative Innovation and Transformation Center” to promote innovation and transformation of results of medical diagnostic technology application;- Collaboration with The Central University of Finance and Economics, Greater Bay Area Research Institute to jointly build an industry-education fusion talent cultivation highland and an industry aggregation and incubation platform.The strategy for sustainable development drives long-term valueWhile vigorously driving business development, Yunkang has consistently viewed sustainable development as a core strategy of the Group, committed to promoting the green transformation of the healthcare industry through innovative technologies and in-depth services. The Group engaged in environmental protection efforts such as energy conservation, emission reduction, and resource recycling in its operations, while also launched various charitable initiatives, including charitable clinical diagnostic activities, health checkup services for the well-being of the community, and health seminars, to give back to society by making use of its professional advantages. Looking ahead, Yunkang will continue to make progress in ESG and step up our efforts in such areas as environmental policy and management, Scope 3 emissions, climate governance, climate performance indicators, climate scenario analysis, carbon reduction targets, and net-zero emissions commitment, all of which will help us realize economic, environmental and social benefits.Future prospectsChina has continued to promote expansion and downward penetration of the country’s high-quality medical resources, fostering a balanced regional layout and stepping up the construction of a hierarchical diagnosis and treatment system, conducive to establishing close-knit medical institution alliances. China’s Laboratory Developed Testing methods (LDT) pilots have steady and notable progress, leading to market growth for precision medicine development. In addition, in-depth integration of AI technology with the healthcare industry will become an important driving force for fine industry segments to embark on digital intelligence transformation and upgrade. Looking ahead, Yunkang will continue to align with national policies, seize the latest industry development opportunities, and continue to strengthen clinical-empowered value, and constantly explore and deepen the two new “product innovation + model innovation” model with customers in mind and to ensure residents can better benefit from its medical achievements.Yunkang Group Limited（Stock Code：2325）Yunkang Group is a leading medical operation service provider in China, which started to provide standardized medical diagnostic services to medical institutions at all levels as early as 2008. Leveraging its own professional diagnostic capabilities and the nationwide service network of integrated healthcare systems, Yunkang has gradually grown to become a medical operation service platform. Meanwhile, Yunkang is a medical operation service provider in China offering a full suite of diagnostic testing services which are diagnostic outsourcing services and diagnostic testing services for medical institution alliances. Yunkang provides diagnostic services through on-site diagnostic centers to collaborative hospitals in the integrated healthcare systems in China and assists them in improving their clinical diagnosis capabilities through co-developing diagnostic centers. As of today, Yunkang has successfully provided professional services to 430+ on-site diagnostic centers. As of December 31, 2024, the hospitals we collaborated with were located across 31 provinces and municipalities in China. Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Mar 31, 2025 - (ACN Newswire via SeaPRwire.com) - Asiaray Media Group Limited (“Asiaray” or the “Group”; stock code: 1993), an established out-of-home (“OOH”) media company with a strategic focus on advertising media management at mass transportation hubs, including airports, metro stations and high-speed rail stations, has announced its annual results for the financial year ended 31 December 2024 (the “Year”). The Group recorded a net profit of RMB10.4 million, compared with a loss of RMB9.9 million in 2023, despite a challenging macroeconomic environment.Mr. Vincent Lam JP, Chairman and Executive Director of Asiaray, said, “I am pleased to report that Asiaray has achieved a turnaround, which not only marks a financial milestone, but also demonstrates our ability to adapt to the evolving market landscape. We have improved operational efficiency by divesting underperforming assets and enhancing retained media resources. We also reacquired operating rights of high-potential media resources at competitive costs and streamlined our operations for better internal control. We continue to leverage our industry expertise to provide creative solutions that empower long-standing clients, especially in the dynamic mass consumption sector, to achieve brand breakthroughs with measurable results, strengthening our network and seizing new opportunities.”For the year ended 31 December 2024, despite a decline in revenue to RMB1,069.2 million due to a decrease in media resource inventory from optimization initiatives, gross profit was RMB306.7 million, with the gross margin improving by 6.8 percentage points from 21.9% in 2023 to 28.7%. Earnings before interest, taxes, depreciation and amortization (EBITDA) amounted to RMB593.2 million. As of 31 December 2024, the Group was in a healthy financial position with cash and cash equivalents, including restricted cash amounting to RMB232.5 million, laying a solid foundation for its business recovery.Business ReviewThe Metro Lines and Billboards business recorded revenue of RMB399.6 million, with gross profit of RMB103.8 million and a gross profit margin of 26.0%. For metro operations, the Group leveraged its expertise and market insights to secure more favorable terms when renewing key metro media resources such as Shenzhen Metro, which delivered solid results. Meanwhile, established assets such as Hangzhou Metro performed stably in line with expectations. Additionally, the growing prominence of high-speed rail as a preferred mode of travel has enhanced the advertising value at hubs such as Hong Kong’s West Kowloon Station and Kunming Railway Station, supported by steady passenger flows and the Group’s business synergies derived from the resources in the Greater China region. The billboard business continued to improve through the diversification of media formats, including the gradual improvement of billboard effectiveness through tailored adjustments.As for the performance of the Airports business, it recorded segment revenue of RMB358.3 million, gross profit of RMB124.5 million and a gross profit margin of 34.8%, representing a year-on-year increase of 8.2 percentage points. The improvement in profitability was driven by the optimization of the Group’s airport media portfolio through continuous resource rationalization, including the regained advertising and media contracts for Haikou Meilan International Airport, for which costs were substantially reduced. While the full operational restructuring is still ongoing, encouraging progress was made during the Year, confirming the effectiveness of the current strategy to improve returns.Regarding the Bus and Other businesses segment, it recorded revenue of RMB311.4 million, gross profit of RMB78.4 million and a gross profit margin of 25.2%, a year-on-year increase of 14.3 percentage points. By formally terminating underperforming contracts in the second half of the year, this segment streamlined operations and enhanced efficiency, resulting in a return to stable performance.During the Year, the Group continued to leverage its industry-leading Outdoor and Online (“O&O”) New Media Strategy and Digital Out-of-Home Plus (“DOOH+”) platform, earning 45 accolades from influential industry platforms for innovative campaigns. The group has fully leveraged its deep market insights, decades of expertise, and economies of scale, combining creativity to connect brands with audiences while prioritizing efficiency, rapid execution and cost-effectiveness. Notable projects included a collaboration with a globally renowned beverage brand, which was awarded the OOH Contextual Marketing Award[1]. The Group redesigned a subway station using the brand’s signature colors, transforming the space into a vibrant brand showcase. Coinciding with the buzz around the Paris Olympics, the campaign incorporated athletic track motifs and Olympic ring installations to amplify the theme of “cheering for athletes”. In Hong Kong, the Group won the prestigious IAI Awards[2] by reimagining bus stops for an international beer brand, integrating atmospheric lighting to create an immersive nighttime experience that offered pedestrians a fresh perspective.On the supply side, the Group strengthened its partnership with programmatic advertising leaders such as The Trade Desk, Hivestack by Perion and Vistar Media, seamlessly connecting its premium OOH media resources with global advertisers seeking precise, data-driven advertising solutions. For example, a telecom brand targeting tech-savvy, data-heavy mobile users leveraged the Group’s media resources across Singapore’s Thomson-East Coast Line via programmatic platforms. Coupled with the Group’s Weather Triggering technology, creatives dynamically switched between “sunny” and “rainy” versions based on real-time weather to complete the offline-to-online cycle, enabling the brand to chase away the rainy day blues by offering customers free data whenever it rained in Singapore. This real-time customization boosted engagement by aligning incentives with immediate scenarios, adding interactivity and playful relevance. These efforts not only enriched urban visual landscapes but also demonstrated the strategic balance between innovative impact and operational agility.ProspectsLooking ahead to 2025, supported by the Chinese government’s initiatives to boost domestic consumption, the Group aims to strengthen its partnership with sectors aligned with current consumption patterns. By harnessing its strategically located media resources across airports, metro systems, and high-speed rail networks, the Group will continue to deliver campaigns that link brand objectives with consumer trends, enabling the creation of targeted and innovative advertising solutions designed to broaden revenue streams and strengthen market position.For the longer term, the Group remains committed to refining its internal control and adopting prudent financial practices that mitigate risk and allow it to navigate the evolving business landscape. Meanwhile, the Group will continue to optimize its media portfolio through long-standing partnerships with major media resource owners, enhancing profitability while maintaining operational efficiency. These initiatives will be supported by organizational restructuring to better align with ever-changing market demands and opportunities.Mr. Lam concluded, “The year 2024 has highlighted a fundamental truth: challenges, when met with clarity and determination, can become catalysts for new beginnings. Innovation remains at the heart of our strategy as we push the boundaries of advertising technologies, optimizing campaigns and turning insights into impact. Building on our leadership in Greater China’s transport advertising sector, we will expand cross-media solutions that connect brands with evolving consumer demands. Leveraging our agility, deep market expertise, and strategic foresight, Asiaray will continue to turn industry shifts into opportunities, delivering long-term value for shareholders and stakeholders while reinforcing our legacy of resilience and innovation.”About Asiaray Media Group Limited (stock code: 1993.HK)Established in 1993, Asiaray is an out-of-home media company in Greater China with a strategic focus on managing mega transport advertising media, including airports, metro lines, and high-speed rail lines. As of now, the Group’s business network spans nearly 40 cities in Greater China, with advertising media resources available at over 24 airports (including exclusive concession rights at 22 airports); providing exclusive advertising media resources in a total of 15 metro lines, including the Singapore Thomson-East Coast Line (TEL), and a total of16 high-speed rail line and railway stations, including the High-Speed Rail Hong Kong West Kowloon Station and the China-Laos Railway (Yumo Line). Additionally, the Group has been granted exclusive advertising media resources at the Hong Kong-Zhuhai-Macao Bridge (Zhuhai Port), as well as on KMB and LWB bus shelters. In recent years, the Group has actively engaged in programmatic advertising transactions with various ad-tech partners such as Google, Hivestack by Perion and The Trade Desk.Asiaray is also dedicated to investing in corporate social responsibility and environmental protection initiatives. The company has received the “Hong Kong Green Organisation” award and has been recognised as a “Caring Company”.For more detailed information about Asiaray, please visit its official website: www.asiaray.com or follow the Group’s WeChat official account via the QR code provided (ID: asiaray_airport˜).[1] The OOH Contextual Marketing Award serves as an industry benchmark and has been held for nine consecutive years. It aims to identify outstanding cases that best represent the innovative spirit and communication value of OOH contextual marketing from numerous entries, thereby driving industrial development. Recognized as one of the most authoritative awards in China’s advertising sector, it maintains rigorous evaluation standards and systematic selection mechanisms.[2] The renowned IAI AWARDS was founded in 2000, co-organized by the China Advertising Association of Commerce and the School of Advertising of Communication University of China. Its jury panel of around 200 members includes influential figures from the academic, advertising, corporate, and media sectors, demonstrating its high recognition in the industry. Copyright 2025 ACN Newswire via SeaPRwire.com.

ATLANTA, GA, Mar 31, 2025 - (ACN Newswire via SeaPRwire.com) - Despite fears of job loss, Quality Assurance (QA) professionals are leaning into AI faster than ever, according to Katalon’s newly released 2025 State of Software Quality Report. The report reveals that testers using AI tools are twice as likely to fear being replaced by them, a paradox that underscores the profession’s evolving relationship with automation. Yet those with stronger AI fluency aren’t just adapting—they’re testing faster, leveling up their skills, and reclaiming joy in the work that once burned them out.Source: Katalon, 2025 State of Software Quality Report, https://www.katalon.com That shift is fueled by both urgency and intent. As AI reshapes expectations, 82% of QA professionals say AI skills will be critical in the next 3 to 5 years, and teams are already adapting. The report finds that those with higher AI fluency excel not just at using new tools, but in test planning, problem-solving, and applying AI concepts in real-world scenarios.To close the skills gap, 67% of teams are investing in continuous learning, while 53% are adopting AI-driven testing practices to stay ahead. And for the most advanced teams, QA is no longer just a safeguard, it’s a business enabler. In fact, 77% of respondents say aligning QA with business goals has helped improve customer retention.Katalon’s 2025 State of Software Quality Report surveyed over 1500 quality professionals, from engineers to senior executives, across North America, Europe, and Asia-Pacific. The report explores the challenges, capabilities, and innovations shaping today’s testing landscape—and how QA teams are evolving from execution-focused roles to strategic drivers of business value.“The shift toward AI-powered testing isn’t just accelerating—it’s inevitable. This year’s report validates what we’ve long believed: QA professionals, the unsung heroes of software innovation, are navigating intense pressure to move faster without compromising quality, and their impact is finally being recognized, with 48% of organizations now viewing QA as a competitive advantage. Looking ahead, the future of quality will belong to teams who can combine AI fluency with human insight to lead testing into a smarter, more adaptive era.”– Vu Lam, CEO of KatalonKey highlights of Katalon’s 2025 State of Software Quality Report:* AI Integration with Human Expertise: Testers who blend AI, automation, and manual testing skills with critical thinking, the new generation of hybrid testers—are leading the next wave of innovation in software quality. According to the report, high-maturity QA teams that leverage these hybrid testers are 1.3 times more likely to adopt AI-augmented test optimization and 1.8 times more likely to implement intelligent test maintenance practices like self-healing tests, compared to lower-maturity teams.* The Happiness Edge: Happier QA pros aren’t just more satisfied, they’re more effective. According to the report, they’re 1.4 times more likely to implement advanced automation solutions (46% vs. 34%) and 1.4 times more likely to say AI has improved efficiency and automation in their roles (71% vs. 52%). As organizations modernize, these findings reveal a clear connection between job satisfaction and innovation in software quality.* AI and The Future of QA: AI-driven testing is gaining momentum, with 61% of QA teams adopting it to automate repetitive tasks and free up time for more strategic work. Forward-looking teams are embracing advanced automation tools, augmented with AI, with the potential to make testing more adaptive, efficient, and intelligent. Beyond AI, they’re also investing in performance and load testing tools (34%) and test management platforms (30%) to further optimize workflows and scale quality with confidence.* Redefine quality with AI: The research shows that high-performing teams are modernizing on three critical fronts: 61% are adopting AI-driven tools, 51% are using modern development practices, and 40% are investing in continuous testing. Together, these shifts are accelerating release cycles while preserving what matters most: trust, reliability, and quality at scale.Resources* Download the full report katalon.com/SoSQR2025* Explore the future of software quality katalon.comSave your seat for the April 24 virtual summit katalon.com/webinars/quality-horizon. Join Katalon, industry experts, and QA leaders to discuss key findings from the report and what’s next for AI in testing.About KatalonKatalon is the category leader in AI-augmented software testing, empowering hybrid testers—those blending manual, automation, and AI skills, to deliver exceptional digital experiences. Trusted by more than 30,000 QA and DevOps teams across 80+ countries, Katalon has been named a G2 Leader in software testing for 11 consecutive quarters. Founded in 2016 and headquartered in Atlanta, Katalon helps teams accelerate software delivery and elevate quality through a powerful, integrated test automation platform, empowering them to release with speed and confidence.Contact:Arati Mukerji commarati@gmail.com +91-9958895759Ms Nhung (Rosie) Nguyen nhung.nguyen@katalon.com +84-039689137 Copyright 2025 ACN Newswire via SeaPRwire.com.